Johnson & Johnson [JNJ] vs Amgen [AMGN] Detailed Stock Comparison
Johnson & Johnson
NYSE
Loading...
Amgen
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Johnson & Johnson wins in 11 metrics, Amgen wins in 9 metrics, with 0 ties. Johnson & Johnson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Johnson & Johnson | Amgen | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 19.04 | 22.62 | Johnson & Johnson |
| Price-to-Book Ratio | 5.46 | 20.03 | Johnson & Johnson |
| Debt-to-Equity Ratio | 64.69 | 756.65 | Johnson & Johnson |
| PEG Ratio | 1.06 | 0.25 | Amgen |
| EV/EBITDA | 15.23 | 12.20 | Amgen |
| Profit Margin (TTM) | 25.00% | 18.96% | Johnson & Johnson |
| Operating Margin (TTM) | 28.91% | 32.73% | Amgen |
| EBITDA Margin (TTM) | 28.91% | 32.73% | Amgen |
| Return on Equity | 30.21% | 99.14% | Amgen |
| Return on Assets (TTM) | 7.61% | 7.51% | Johnson & Johnson |
| Free Cash Flow (TTM) | $18.06B | $10.39B | Johnson & Johnson |
| Dividend Yield | 2.47% | 4.09% | Amgen |
| 1-Year Return | 7.58% | -16.83% | Johnson & Johnson |
| Price-to-Sales Ratio (TTM) | 4.73 | 4.26 | Amgen |
| Enterprise Value | $460.71B | $196.97B | Johnson & Johnson |
| EV/Revenue Ratio | 5.08 | 5.64 | Johnson & Johnson |
| Gross Profit Margin (TTM) | 67.87% | 67.20% | Johnson & Johnson |
| Revenue per Share (TTM) | $38 | $65 | Amgen |
| Earnings per Share (Diluted) | $9.35 | $12.22 | Amgen |
| Beta (Stock Volatility) | 0.39 | 0.48 | Johnson & Johnson |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Johnson & Johnson vs Amgen Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Johnson & Johnson | -0.25% | -0.21% | 3.06% | 13.66% | 9.34% | 23.64% |
| Amgen | -2.24% | -2.56% | -3.01% | -7.03% | -11.56% | 6.60% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Johnson & Johnson | 7.58% | 6.24% | 19.36% | 90.66% | 189.20% | 173.18% |
| Amgen | -16.83% | 19.62% | 11.61% | 83.60% | 400.71% | 225.82% |
News Based Sentiment: Johnson & Johnson vs Amgen
Johnson & Johnson
News based Sentiment: POSITIVE
September was a positive month for Johnson & Johnson, driven by strong Q2 earnings, increased guidance, and continued investment in growth areas like biomanufacturing. While challenges remain, the overall narrative points to a resilient and well-positioned company, making it a favorable investment option.
Amgen
News based Sentiment: POSITIVE
Amgen demonstrated a strong financial performance in Q2 2025, exceeding earnings and revenue expectations. Coupled with positive clinical trial data and expanded FDA approval for Repatha, the company appears well-positioned for continued growth, despite mixed analyst sentiment and varied institutional investor activity.
Performance & Financial Health Analysis: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Market Information | ||
| Market Cap | $428.83B | $148.80B |
| Market Cap Category | Mega cap | Large cap |
| 10 Day Avg. Volume | 7,498,410 | 2,148,930 |
| 90 Day Avg. Volume | 8,099,283 | 2,112,570 |
| Last Close | $178.06 | $276.39 |
| 52 Week Range | $140.68 - $181.16 | $253.30 - $339.17 |
| % from 52W High | -1.71% | -18.51% |
| All-Time High | $186.69 (Apr 25, 2022) | $346.85 (Jul 22, 2024) |
| % from All-Time High | -4.62% | -20.31% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.09% |
| Quarterly Earnings Growth | 0.18% | 0.92% |
| Financial Health | ||
| Profit Margin (TTM) | 0.25% | 0.19% |
| Operating Margin (TTM) | 0.29% | 0.33% |
| Return on Equity (TTM) | 0.30% | 0.99% |
| Debt to Equity (MRQ) | 64.69 | 756.65 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $32.61 | $13.80 |
| Cash per Share (MRQ) | $7.84 | $14.91 |
| Operating Cash Flow (TTM) | $23.03B | $12.01B |
| Levered Free Cash Flow (TTM) | $11.08B | $10.42B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.47% | 4.09% |
| Last 12-Month Dividend | $3.72 | $11.64 |
Valuation & Enterprise Metrics Analysis: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 19.04 | 22.62 |
| Forward P/E | 16.80 | 13.37 |
| PEG Ratio | 1.06 | 0.25 |
| Price to Sales (TTM) | 4.73 | 4.26 |
| Price to Book (MRQ) | 5.46 | 20.03 |
| Market Capitalization | ||
| Market Capitalization | $428.83B | $148.80B |
| Enterprise Value | $460.71B | $196.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.08 | 5.64 |
| Enterprise to EBITDA | 15.23 | 12.20 |
| Risk & Other Metrics | ||
| Beta | 0.39 | 0.48 |
| Book Value per Share (MRQ) | $32.61 | $13.80 |
Financial Statements Comparison: Johnson & Johnson vs Amgen
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Revenue/Sales | $21.89B | $8.15B |
| Cost of Goods Sold | $7.36B | $2.97B |
| Gross Profit | $14.54B | $5.18B |
| Research & Development | $3.23B | $1.49B |
| Operating Income (EBIT) | $6.30B | $1.18B |
| EBITDA | $8.72B | $4.08B |
| Pre-Tax Income | $13.63B | $1.97B |
| Income Tax | $2.63B | $243.00M |
| Net Income (Profit) | $11.00B | $1.73B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Cash & Equivalents | $38.47B | $8.81B |
| Total Current Assets | $71.55B | $26.93B |
| Total Current Liabilities | $56.90B | $23.01B |
| Long-Term Debt | $38.36B | $54.01B |
| Total Shareholders Equity | $78.11B | $6.21B |
| Retained Earnings | N/A | $-27.14B |
| Property, Plant & Equipment | N/A | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | JNJ | AMGN |
|---|---|---|
| Operating Cash Flow | $6.35B | $1.71B |
| Capital Expenditures | $-795.00M | $-411.00M |
| Free Cash Flow | $3.37B | $980.00M |
| Debt Repayment | $-2.87B | $-2.50B |
| Common Stock Repurchase | $-2.13B | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JNJ | AMGN |
|---|---|---|
| Shares Short | 18.84M | 11.80M |
| Short Ratio | 2.26 | 5.85 |
| Short % of Float | 0.01% | 0.02% |
| Average Daily Volume (10 Day) | 7,498,410 | 2,148,930 |
| Average Daily Volume (90 Day) | 8,099,283 | 2,112,570 |
| Shares Outstanding | 2.41B | 537.00M |
| Float Shares | 2.40B | 536.99M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.74% | 0.84% |
Dividend Analysis & Yield Comparison: Johnson & Johnson vs Amgen
| Metric | JNJ | AMGN |
|---|---|---|
| Last 12-Month Dividend | $3.72 | $11.64 |
| Last 12-Month Dividend Yield | 2.47% | 4.09% |
| 3-Year Avg Annual Dividend | $3.97 | $9.51 |
| 3-Year Avg Dividend Yield | 0.75% | 0.80% |
| 3-Year Total Dividends | $11.92 | $28.54 |
| Ex-Dividend Date | Feb 18, 2025 | Aug 22, 2025 |